Mesoblast share price dips amid latest class action news

The company is being taken to court by another unhappy shareholder.

| More on:
An unhappy man in a suit sits at his desk with his arms crossed staring at his laptop screen as the PointsBet share price falls

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Mesoblast share price is in the red on Thursday, slipping 1.93% to trade at $1.01
  • The dip comes amid news the company has been hit with another class action
  • Mesoblast has vowed to fight the latest allegations and noted it recently settled a similar suit in the US without admitting liability

The Mesoblast Limited (ASX: MSB) share price is slipping lower as the company is hit with another class-action lawsuit.

A shareholder is suing the biotechnology company alleging it misled the market about its remestemcel-L product.

At the time of writing, the Mesoblast share price is $1.01, 1.93% lower than its previous close.

For context, the S&P/ASX All Ordinaries Index (ASX: XAO) is currently also down 1.41%. Meanwhile, the S&P/ASX 200 Health Care Index (ASX: XHJ) is up 0.26%.

Let's take a closer look at the details.

Mesoblast facing a new class action

The Mesoblast share price is slipping amid news a class action proceeding in the Federal Court of Australia has been served on the company.

Law firm William Roberts Lawyers has brought the action against Mesoblast. The firm is representing a person who bought shares in the company between February 2018 and December 2020.

It alleges the company engaged in unlawful conduct that misled the market about remestemcel-L. 

"Mesoblast will vigorously defend against the proceeding," the company said in a statement published to the ASX.

It also noted it resolved a similar suit in the United States for $2 million without admitting liability in April. The company's insurer covered the cost of the settlement.

Mesoblast has reportedly faced multiple class actions in the US on similar allegations.

Previous actions claimed Mesoblast didn't inform investors about adverse aspects of particular remestemcel-L trials, the Australian Financial Review reported in 2020.

That reportedly prompted the FDA to demand a further controlled study of the drug before it could be given the green light to treat acute graft versus host disease in children.

And it might not be the last time the market hears news of a class action against the company.

Australian law firm Phi Finney McDonald has also been looking into a class action against Mesoblast over the past few months.

Mesoblast share price snapshot

This year has been rough on the Mesoblast share price.

The stock has tumbled nearly 28% year to date. It's also nearly 45% lower than it was this time last year.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »